MADRID, 20 (EUROPA PRESS)

The director of the laboratory of therapeutic targets of Center comprehensive Oncology Clara Campal (CIOCC), Fernando López-Ríos, ensures that personalized medicine is “already a reality” in the treatment of cancer and is allowing that in many tumors can be “avoided the use of indiscriminate therapies”.

So has assured us it on the occasion of a meeting on personalized medicine organized this week by Pfizer, recognizing that “impressive answers” are getting in some types of cancers, including breast, lung, melanoma,.

Personalized medicine is based on the detection of a particular genetic alteration that affects the appearance of cancer, and who becomes the target against which acts treatments led, avoiding the toxicity that had first chemotherapies and achieving “significant improvements in survival” and even its chronicity.

“Is no longer a matter of exclusive of some tumors”, warns this expert, told Europa Press, while recognizing that other cancers such as the brain or sarcomas still have found no therapeutic targets specific.

In his view, “depends on the biology of these tumors, although it is also true that it is perhaps investigating more more frequent tumors”, points López-Ríos.

In any case, the emergence of personalized medicine has made it possible to “already not mention a single disease but many”, explains this expert, who advocates the importance of that work together specialists from different disciplines to ensure that its correct approachable is “feasible”.

In this diagnostic laboratories, play an important role since, as points out Dr. López-Ríos, “the fact that there is a very good drug with a specific molecular disruption that needs to be studied to find out if it is to give this treatment or another is doing to develop new diagnostic methods to locate these genetic markers”.

To this end, currently there are “fully automated” methodological platforms that allow giving a result “very reliable and very little time”, explains the expert.

Addition, although there are many centres for analysis in Spain, the objective is “centralize testing in selected centres of excellence, in order to gain speed and reliability in the results, and contain the cost”.